
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge
By Rajiv Nayar and Mark C. Manning, HTD Biosystms, Inc., pp. 20-28. Outsourcing is often considered a way to expedite drug development, but other options exist for companies that don't choose it yy} or that run up against the capacity shortage. The resources devoted to speeding up the drug discovery process led to combinatorial libraries, high-throughput screening, proteomics, and genomics. Now the same types of innovation can be applied to drug development to prevent valuable lead compounds from sitting idle on the shelf.
Articles in this issue
almost 24 years ago
Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Baralmost 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementalmost 24 years ago
The Immunogenicity of Therapeutic Proteinsalmost 24 years ago
Analytical Advances: Calibration Management of Outsourced Calibrationsalmost 24 years ago
Inside Washington: Costs and Controls Challenge Manufacturersalmost 24 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.





